Elsevier

Cellular Signalling

Volume 6, Issue 7, September 1994, Pages 793-812
Cellular Signalling

Molecular cloninc and expression, in both COS-1 cells and S. cerevisiae, of a human cytosolic type-IVA cyclic AMP specific phosphodiesterase (hPDE-IVA-h6.1)

https://doi.org/10.1016/0898-6568(94)00039-5Get rights and content

Abstract

Screening a human T lymphocyte cDNA library with a phosphodiesterase (PDE) specific probe resulted in the isolation of two overlapping cDNA clones, h2.2 and h6.1, that encode a type IV, rolipram inhibited cAMP-specific PDE. Clones h2.2. and h6.1 were 1015 bp and 2288 bp in length, respectively, and overlapped for 984 bp with only one nucleotide difference. The h6.1 cDNA was extended at the 5′-end by 1304 pb, with respect to h2.2, and encoded an incomplete ORF (lacking an initiation codon) of 668 amino acids. The merged nucleotide sequence of h6.1/h2.2 exhibited 99.5% homology in the ORF (ten nucleotide changes resulting in six amino acid changes), and 95% homology in the 3′-untranslated region, with the previously reported human PDE-IVA cDNA [Livi G.P., Kmetz P., Mchale M.M., Cieslinski L.B., Sathe G.M., Taylor D. P., Davis R.L., Torphy T. J. and Balcarek J. M. (1990) Mol. Cell Biol.10, 2678–2686]. The sequence reported for h6.1/h2.2 matched that found for IVA clones isolated from three other human cDNA libraries, a human genomic cosmid clone and pcr amplified products of the exon covering these differences in two individuals. The h6.1 cDNA was engineered to generate a complete OFR by building in the the 56 bp, including the initiation codon, present in hPDE-IVA-Livi and missing from the 5′-end of h6.1, producing a cognate ORF encoding a protein of 687 amino acids but differing in five amino acids which lay in or adjacent to the putative catalytic domain. The complete h6.1 ORF was engineered for expression in both Saccharomyces cerevisiae and in COS-1 cells. Integration of single copy of the engineered ORF of h6.1, under the transriptional control of a constitutive yeast promoter, at the pep4 locus of a S. cerevisiae strain lacking both yeast PDE genes resulted in functional complementation of the yeast pde-phenotype. Yeast strains with functional PDE were a light creamy white colour, while strains devoid of PDE activity wre a dull brown colour. Expression of h6.1 in COS-1 cells led to the production of a typical type IV PDE activity in the cAMP, but not cGMP, served as substrate and its activity was insensitive to either Ca2+CaM or cGMP but was inhibited by low concentrations of rolipram. The h6.1 PDE activity was found exclusively (> 95%) in the soluble cytosol fraction of COS-1 cells where it exhibited a Km of 6 ± 2 μM for cAMP and an IC50 value of 0.6 ± 0.2 μM for rolipram, using 3 gmM cAMP as substrate. We suggest that the sequence of the h.2.2/h6.1 cDNA, presented here, represents more closely the sequence of one of the splice variants of the human type IVA PDE (HPDE4A) than that reported (as cited above).

References (40)

  • T. Michaeli et al.

    J. biol. Chem.

    (1993)
  • M.M. McLaughlin et al.

    J. biol. Chem.

    (1993)
  • M. Schena et al.

    Meth. Enzym.

    (1991)
  • D.M. Becker et al.

    Meth. Enzym.

    (1991)
  • R.S. Sikorski et al.

    Meth. Enzym.

    (1991)
  • M.M. Bradford

    Analyst. Biochem.

    (1976)
  • W.J. Rutten et al.

    Biochim. biophys. Acta

    (1973)
  • G.P. Livi et al.

    Molec. cell Biol.

    (1990)
  • J.A. Beavo
  • M.D. Housley et al.
  • M. Conti et al.

    Endocr. Rev.

    (1991)
  • B.E. Lavan et al.

    Biochem. Pharmac.

    (1990)
  • M.D. Houslay

    Cell Signal.

    (1991)
  • M.L. Reeves et al.

    Biochem. J.

    (1987)
  • R.J. Marchmont et al.

    Biochem. J.

    (1980)
  • R.L. Davis et al.
  • J. Colicelli et al.
  • C.N. Chen et al.
  • M. Conti et al.
  • R.L. Davis
  • Cited by (40)

    • Differential type 4 cAMP-specific phosphodiesterase (PDE4) expression and functional sensitivity to PDE4 inhibitors among rats, monkeys and humans

      2004, Biochemical Pharmacology
      Citation Excerpt :

      Functionally, the sensitivity of the various species to PDE4 inhibitors was compared using lipopolysaccharide-induced TNF production in total blood leukocytes, since the TNF production assay is highly sensitive to PDE4 inhibition [25,29,30]. In this assay the three PDE4 inhibitors tested, each with a different mechanism of inhibition [20–25], showed an order of potency identical to the order of PDE4 enzyme activity level (i.e. rat > monkey > human) (Table 3). In addition, a PE-induced renal artery contraction assay was used to further assess the sensitivity to PDE4 inhibitors between rats and humans, in light of the fact that arteriopathy has been considered to be a serious “class effect” of PDE4 inhibitors in rats [5–7].

    • Cyclic nucleotide phosphodiesterases: Relating structure and function

      2000, Progress in Nucleic Acid Research and Molecular Biology
    View all citing articles on Scopus

    Present address: Fisonz Pharmaceuticals, Bakewell Rd, Loughborough LE11 0RH, U.K.

    §

    Present address: Zeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire SK10 4TH, U.K.

    View full text